tbuckley/cabot-search huggingface dataset:
OC-025 Application of a Survival Nomogram for Palliative Cancer Patients on Home Parenteral Nutrition: Is It Valid?
Authors: S Oke, D Ismail, M Stroud, T Smith, SM Gabe, M Naghibi
Journal: Gut (2016)

<h3>Introduction</h3> Home parenteral nutrition (HPN) for palliative malignancy is increasing and optimal selection of patients remains challenging. A nomogram predicting survival length<sup>1 </sup>based on Glasgow prognostic score (CRP and albumin), primary cancer, metastases &amp; Karnofski performance status has recently been developed. In the nomogram survival was calculated from discharge date, rather than the date of PN commenced. We aimed to test the validity of the nomogram by retrospectively applying it to a cohort of HPN palliative cancer patients at St Mark's Hospital &amp; University Hospital Southampton. <h3>Methods</h3> Adult patients with palliative cancer started on HPN were identified between 1/1/05 and 1/12/15. Patients were excluded with a diagnosis of psuedomyxoma or if a cancer developed while on HPN. Karnofski performance status was assigned though MDT discussion. <h3>Results</h3> 47 patients met the inclusion criteria, 44 patients had sufficient data to complete the nomogram. There were 9 ovarian, 26 GI and 9 'other' cancers (metastasis in 77%). Median survival for ovarian cancers was 100 days, GI cancers 55 days &amp; other primaries 15 days. The nomogram over or underestimated survival length by ≤25%, 25–50%, ≥50% in 40%, 20% and 40% of patients, respectively. 12 patients were predicted to live &lt;2 months, which was correct for 8 (67%). The mean overall difference in survival compared the nomogram prediction was 66 +/-59 days (95% CI). Figure 1, shows Kaplan-Meier curves for actual vs. predicted survival (log rank (Mantel-Cox) test p = 0.006) confirming significant difference. <h3>Conclusion</h3> This data does not validate the use of this nomogram to predict survival length in HPN palliative malignancy patients. In our cohort the data shows that this nomogram most often under estimates survival. The retrospective nature of this study and relatively small number of patients is a limiting factor. Further prospective studies are needed and it is recommended defining survival as measured from date PN commenced. At present the best judge for considering palliative HPN is clinical acumen &amp; patient performance status. <h3>Reference</h3> 1 Bozzetti F, Cotogni P, Lo Vullo S, Pironi L, Giardiello D, Mariani L. Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutrition. <i>Ann Oncol</i> 2015;<b>26</b>(11):2335–2340. <h3>Disclosure of Interest</h3> None Declared
FRI0400 A Five Year Prospective Study of Spinal Radiographic Progression in Patients with Ankylosing Spondylitis
Authors: A. Deminger, E. Klingberg, M. Geijer, J. Göthlin, M. Hedberg, E. Rehnberg, H. Carlsten, L.T. Jacobsson, H. Forsblad-d'Elia
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The knowledge about what predicts progress of syndesmophytes that characterize patients with ankylosing spondylitis (AS) is limited. The strongest known predictor for radiographic progression in the spine is existing syndesmophytes at baseline. <h3>Objectives</h3> To study the radiographic progression in the spine in AS patients in total and by gender and search for predictors for the changes. <h3>Methods</h3> 204 patients with AS, all meeting the New York criteria, from three rheumatology departments in western Sweden were included in a longitudinal study. At baseline and after five years lateral radiographs of the cervical and lumbar spine were obtained and graded according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). All radiographs were assessed by the same experienced radiologist (MG). Predictors were assessed through questionnaires, back mobility tests and blood samples. <h3>Results</h3> Of the 204 patients included at baseline, 169 (83%) patients were re-examined at the five year follow-up, 92 (54%) men and 77 (46%) women. At baseline, the median age (IQR) of the 169 patients was 49 (40 to 61.5) years old and the median duration of symptoms (IQR) was 22 (12 to 34) years, no significant difference in age or duration of symptoms between gender. Baseline mean mSASSS was 14.9±20.0 with progression to 16.4±20.8 at follow-up, an increase with 1.5±3.0 units (p&lt;0.001). In men, mean baseline mSASSS was 22.0±23.5 and at follow-up 23.8±23.8, an increase of 1.8±2.8 units (p&lt;0.001). In women, mean baseline mSASSS was 6.4±9.6 and 7.6±11.7 at follow-up, an increase of 1.2±3.3 (p=0.002). The mSASSS score at both baseline and at follow-up differed significantly between gender (p&lt;0.001), whereas the progression of mSASSS did not differ significantly (p=0.2) between the groups. The presence of syndesmophytes at baseline was 47% in the whole group, 59.0% for men and 32.5% for women (p-value difference gender &lt;0.001). In the total group 18.9% had had significant progression (≥4 mSASSS units over five years), 23.9% of the men and 13.0% of the women (p=0.11). Such rapid progression of mSASSS was in age-adjusted logistic regression models significantly predicted by baseline syndesmophyte and mean CRP during follow-up in men and baseline BASMI in women (table). <h3>Conclusions</h3> The progression rate was 1.5±3.0 mSASSS units over five years and did not differ significantly between men and women, although being much higher in men at baseline in this cohort of AS patients with longstanding disease. Presence of existing syndesmophytes and persistent elevated CRP during follow-up were significant predictors for a change in ≥4 mSASSS units over five years in men whereas in women instead high BASMI was a significant predictor. <h3>Disclosure of Interest</h3> None declared
AB0232 Neuropathic Pain in Patients with Rheumatoid Arthritis: A Cross-Sectional Study
Authors: O. Akkar, M. Lehraiki, H. Azzouzi, L. Boutouala, L. Ichchou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) pain is traditionally attributed to peripheral inflammation of the joints. However, pain control is often inadequate, even when inflammation appears to be well controlled. This suggests that neuropathic pain (NP) may also be present in patients with RA. <h3>Objectives</h3> The objective of this study was to examine NP symptoms and associated factors in patients with RA. <h3>Methods</h3> Patients with RA according to ACR 1987 or ACR/EULAR 2010 classification criteria were included in this cross-sectional study. Demographic data and RA characteristics were collected. Pain was measured using a visual analogue scale (VAS). Disease activity was assessed by the Disease Activity Score (DAS 28). Functional disability was evaluated by the Health Assessment Questionnaire (HAQ). Joint destruction was assessed by the Van der Heijde-modified Sharp Score. NP symptoms were assessed using the DN4 questionnaire. Data analysis was carried out using the SPSS 20 Software. p&lt;0.05 was considered statistically significant. <h3>Results</h3> Eighty-four patients with a mean±SD age of 50.6 ±12.29 years were enrolled. Eighty-nine per cent were female. Mean±SD duration of symptoms was 11.24±8.91 years. Thirty one per cent had NP and 96.2% of them were taking steroids. In the NP group, means±SD of VAS pain, DAS28, HAQ, sharp score were 3.85±2.73, 3.21±2.21, 1.00±0.95 and 63.27±43.52 respectively. NP patients did not significantly differ from those with no NP symptoms in terms of age, disease duration, disease activity, VAS pain, functional disability and joint destruction. The regression analysis showed that there was no significant correlation between NP and the RA parameters. <h3>Conclusions</h3> The prevalence of NP was 31% in our RA population. It is important to consider the existence of NP in the assessment and treatment of RA pain. However, larger studies are needed to investigate factors associated with NP in RA patients. <h3>Disclosure of Interest</h3> None declared
Distinct Cytogenetic Aberrations during the Course of Mantle Cell Lymphoma (MCL).
Authors: Stephanos I. Papadhimitriou, Ageliki Davea, Ioanna Savvidou, George Paterakis, Helen Goumakou, Elpi Griva-Kritikou, George Androutsos, Dimitris Pavlidis, Theodoros Marinakis, Nikolaos I. Anagnostopoulos, Maria Georgiakaki
Journal: Blood (2006)
Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study.
Authors: Asher Alban Chanan-Khan, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Facon, Jean-Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna E. Reece, Rachel B. Neuwirth, Kenneth C. Anderson, Paul G. Richardson
Journal: Blood (2006)
Secondary Antifungal Prophylaxis with Liposomal Amphotericin B (AmB-L) in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Alessandro Busca, Stefano D’Ardia, Elisabetta Terruzzi, Enrico Pogliani, Emilio Paolo Alessandrino, Vassiliki Griva, Giorgio Lambertenghi Deliliers
Journal: Blood (2007)
SP0006 The IL-17 Pathway in The Pathogenesis of SPA: Focus on Structural Damage
Authors: D. Baeten
Journal: Annals of the Rheumatic Diseases (2016)

The IL-17 pathway is now firmly established to play a central role in the pathogenesis of axial and peripheral SpA. The evidence from genetics, functional studies, experimental models, and human expression analysis has been confirmed by phase III clinical trials with anti-IL17A antibodies in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) showing a profound suppression of signs and symptoms of inflammation. Interestingly, these trials also showed a suppression of articular destruction in PsA and low mSASSS progression rates in AS. A key scientific and clinical question is thus how and to what extend the IL-17 pathway contributes to structural damage in SpA. The role of IL-17A in driving osteoclast maturation and activation is well understood. Its potential role in new bone formation, however, remains much more controversial. Recent animal experiments indicate that IL-17A may suppress osteoblast activity and new bone formation by inhibition of Wnt signaling. In contrast, however, work in the HLA-B27 tg rat model showed that IL-17A inhibition halts pathological axial and peripheral osteoproliferation. Albeit this may be an indirect effect related to suppression of inflammation, bone formation experiments with human cells indicate a direct osteoblast-promoting effect of IL-17A. This concept is further supported by recent studies in bone fracture models. The differential effects of IL-17 family members on bone formation illustrates well that the functional outcome of cytokine signaling is highly dependent on the exact cellular and immunological context in which it is occurring, with important difference between mice and humans. Further translational studies in human patients are needed to establish whether IL-17 blockade may not only suppress inflammation but also halt both catabolic and anabolic aspects of structural damage in human SpA. <h3>Disclosure of Interest</h3> None declared
Obesity and Other Cancers
Authors: Lin Yang, Bettina F. Drake, Graham A. Colditz
Journal: Journal of Clinical Oncology (2016)

Purpose Evidence on overweight, obesity, and an increased risk of cancer continues to accumulate and was updated in the 2016 handbook on weight control from the International Agency for Research on Cancer (IARC). The underlying primary data, together with dose-response meta-analysis and, finally, pooled analysis of individual participant data, add insight into the relation between obesity and cancer risk and prognosis. We summarize the evidence for mortality from prostate cancer, hematologic malignancies, and kidney cancer. Methods We reviewed pooled analysis of rare end points across cohorts, regardless of primary results reported from the individual studies, further reducing risk of publication bias. Of these cancer sites, only kidney cancer was included in the IARC 2002 report, although mortality from prostate cancer and hematologic malignancies was noted in the American Cancer Society prospective cohort study in 2003. The 2016 update from the IARC added details for prostate and hematologic malignancies, classifying the evidence as sufficient to conclude that avoiding excess body fatness lowers the risk of multiple myeloma but found that the evidence for it lowering the risk of prostate cancer mortality or diffuse large B-cell lymphoma was limited. Results A higher body mass index is associated with an increased risk of advanced prostate cancer and prostate cancer mortality and is associated with worse survival in most subtypes of hematologic malignancies, in a dose-response fashion. Evidence for kidney cancer is built mostly on retrospective data, which supports an obesity paradox in patients with the clear cell variant; however, population-based cohort data indicate that a higher cohort-entry body mass index is associated with worse kidney cancer–specific survival. Conclusion Together, these data add support to the evidence for a growing cancer burden caused by adiposity in both early adult and later adult life, yet leave open the question of the means of weight management after diagnosis as a strategy to improve survival.
PTH-104 Hospital Admissions and Associated Costs of Alcoholic Liver Disease in Scotland Between 1991 and 2011
Authors: J Lewsey, J Blutell, C Geue, G Antony, A Briggs, G McCartney, S Hutchinson, L Graham, M Heydtmann
Journal: Gut (2016)

<h3>Introduction</h3> Alcoholic liver disease and its associated hospitalisations due to acute and chronic liver disease is a significant worldwide problem with Scotland having worse statistics than most European and Western countries with regards to health burden including mortality and healthcare costs. This <b>SC</b>ottish <b>A</b>lcoholic <b>L</b>iver disease <b>E</b>valuation (SCALE) study was set up to identify a cohort of people hospitalised for the first time with Alcoholic Liver Disease (ALD) in Scotland from 1991 to 2011 and identify trends in these incident admissions, in-hospital mortality, readmissions and mortality after discharge as well as life time costs compared to controls. <h3>Methods</h3> Hospital records from 1981 to 2011 were used to identify cases of ALD presenting 1991–2011 with no prior hospitalisation due to ALD. These incident cases were classified by sex, age group, socio-economic deprivation and study year as well as decompensated or not decompensated ALD. In-hospital mortality, time to all cause death, readmissions and related hospital costs were calculated by length of stay and hospital-specific per diem cost and compared to matched controls. Parametric survival analysis was used to estimate remaining life expectancy and remaining lifetime hospitalisation related costs were calculated. <h3>Results</h3> We identified 35,208 incident ALD admissions over the period 1991 to 2011. Incident ALD hospitalisation rates decreased between 2002 and 2011(Men: 63 to 54; Women: 27 to 24 per 100,000). Inpatient mortality was 17.4% during the index admission. 5 (10) year mortality post-discharge was 59% (74%) for patients with decompensated ALD and 49% (65%) without. The mean (median) number of readmissions per year was 3.1 (1.3). The estimated annual cost of hospitalisation for the remaining life of a man, aged 50, living in the most deprived SIMD fifth with an incident ALD admission in 2011 was £ 118,000 higher compared to matched controls. <h3>Conclusion</h3> After a peak in 2007 / 2008 incident rates of ALD fell in Scotland but remain high in comparison to the epidemiological literature. Prognosis for incident cases of ALD is poor and costs associated with incident ALD cases are very high compared to matched controls. <h3>References: Acknowledgements</h3> Chief Scientist Office, Scotland for the project ‘SCottish Alcoholic Liver disease Evaluation of epidemiology and costs of first and subsequent hospital admissions (SCALE). <h3>Disclosure of Interest</h3> None Declared
AB0872 Switching of Biologic Treatment in One Paediatric Rheumatology Centre. Retrospective Review: Table 1
Authors: K. Khawaja, B. Ayyash, M. AlMaini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The treatment of children with rheumatic and musculoskeletal diseases (RMD) have changed significantly with biologic treatment. <h3>Objectives</h3> To look at reasons for switching from one biologic to another. <h3>Methods</h3> Patients with confirmed RMD identified in our centre using The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), from 1st January 2011 to 31st December 2015. Retrospective review of electronic records and paper case notes of patients presented to the centre reviewed using pre-specified Clinical Research Form (CRF). <h3>Results</h3> We identified 181 paediatric patients on continuous follow up. The distribution as follows; juvenile Idiopathic Arthritis (JIA) 78, Systemic Lupus (JSLE) 19, Juvenile Scleroderma (Scl) 5, vasculitis 7, Juvenile Dermatomyositis (JDM) 6, Familial Mediterranean Fever (FMF) 9, Macrophage Activation Syndrome (MAS) 3 and Uveitis only in 2. Other diagnoses of non-inflammatory nature 52 including juvenile osteoporosis, mechanical pain syndromes and vitamin D deficiency. The total number of patients on biological therapy is 35 patients including 33 JIA and 2 JSLE. The number of patients still on the same biologic agent is 25. The following are the biologics with numbers of patients still on the same therapy (25): Etanercept 7 (JIA), Infliximab 3 (JIA), Adalimumab 1 (Uveitis), Abatacept 1 (JIA), Tocilizumab 7 (JIA), Anakina 4 (JIA 3, FMF 1), Rituximab 2 (JSLE). The number of patients who switched their treatment to a second or third agent is 10. The reason for switching biological treatment was lack of efficacy in 7 out of the 10 patients and side effects in the other 3 patients (table 1). Average follow up on current treatment of 36.6 months (range 0.5 to 81 months). <h3>Conclusions</h3> The percentage of patients who switched biological treatment is 28.6% although numbers are small. Reasons for switching biologic treatment in our experience in children with RMD is: -lack of efficacy with persistent inflammation in 7 out of 10. -Side effects of treatment in 3 out of the 10 (Uveitis while on etanercept (2) and one developed MAS twice on canakinumab. <h3>Acknowledgement</h3> To all the children and their families for allowing us to use their data. <h3>Disclosure of Interest</h3> None declared
Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma
Authors: Viet Q. Ho, Elizabeth Finley-Oliver, Kenneth H. Shain, Melissa Alsina, Leonel Ochoa, Taiga Nishihori, Benjamin Djulbegovic, Rachid Baz
Journal: Blood (2011)
Short Term Outcome after Allogeneic Stem Cell Transplantation in 70 Cases of Severe Aplastic Anaemia.
Authors: Parvez Ahmed, Khalil Ullah, Tariq M. Satti, Shahid Raza, Qamar-Un-Nisa Chaudhry, Khalid Kamal, Badshah Khan, Masood Anwar
Journal: Blood (2007)
Change in Trans Fatty Acid Content of Fast-Food Purchases Associated With New York City's Restaurant Regulation
Authors: Sonia Y. Angell, Laura K. Cobb, Christine J. Curtis, Kevin J. Konty, Lynn D. Silver
Journal: Annals of Internal Medicine (2012)

A ban on chain restaurant sale of foods containing trans fats went into effect in New York City in 2008. In 2007 and 2009, receipts were obtained from adult customers exiting chain restaurants in N...
NOTCH1/FBXW7 Mutations, but Not Low ERG/BAALC Expression, Identify a Major Subgroup of Adult T-ALL with a Favorable Outcome: a GRAALL Study.
Authors: Raouf Ben Abdelali, Agnes Buzyn, Vahid Asnafi, Sandrine Le Noir, Norbert Ifrah, Herve Dombret, Elizabeth Macintyre
Journal: Blood (2009)
In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.
Authors: Guntram Buesche, Rudiger Hehlmann, Arnold Ganser, Hartmut Hecker, Andreas Hochhaus, Hermann Heimpel, Barbara Heinze, Claudia Schoch, Dorothea Gadzicki, Martin Mueller, Nils von Neuhoff, Susanne Schnittger, Brigitte Schlegelberger, Bernd Frye, Axel Georgii, Hans Kreipe
Journal: Blood (2006)
Novel Therapeutic Approach Yields Excellent Results in Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Time To Think out of the Box.
Authors: Shripad Banavali, Lovenish Goyal, Bhavana Padhye, Brijesh Arora, Roshni Bhagwat, Sumit Gujral, Chandrika Nair, Purvish Parikh
Journal: Blood (2005)
OP0096 Meniscal Extrusion and Bone Marrow Lesions Are Independently Associated with Incident and Progressive Knee Osteoarthritis
Authors: J. Martel-Pelletier, A.J. Teichtahl, F.M. Cicuttini, F. Abram, Y. Wang, J.-P. Pelletier
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Whether meniscal extrusion and bone marrow lesions (BMLs) independently predict the risk of knee osteoarthritis (OA) remains to be clarified. Yet, while prospective cohort studies have shown that both meniscal extrusion and BMLs increase the risk of progressive knee OA, these studies have focused on the medial rather than the lateral knee joint, and examined people with established knee OA. It remains unclear whether these structural abnormalities predate incident knee OA, or whether meniscal extrusion or BMLs independently predict progressive disease. <h3>Objectives</h3> The aim of this 72 month longitudinal study was to examine whether compartmental baseline meniscal extrusion and BMLs were independently associated with incident and progressive knee OA, as measured by i) cartilage volume loss, ii) incident or progressive radiographic OA (ROA), and iii) total knee replacement (TKR). <h3>Methods</h3> Data was extracted from the Osteoarthritis Initiative (OAI) cohort. Participants were grouped according to the absence (Kellgren-Lawrence (KL) grade ≤1, n=2120) or presence (KL ≥2, n=2249) of ROA. Baseline meniscal extrusion, BMLs and cartilage volume were assessed on magnetic resonance imaging (MRI). Cartilage volume of the tibial plateau was assessed at baseline and 72 months, while ROA was assessed at baseline and 48 months. TKR was assessed at 72 months. <h3>Results</h3> In those with ROA, the presence of a baseline meniscal extrusion (independent of BMLs) was associated with accelerated cartilage loss (medial tibia: -2.1%/annum vs. -1.5%; lateral tibia: -2.6%/annum vs. -1.6%; both p&lt;0.001), progressive ROA and TKR (OR range 1.4 to 1.8; 95% CI range 1.1 to 2.9, p≤0.04). The presence of a baseline BML (independent of meniscal extrusion) was associated with accelerated cartilage loss (medial tibia: -2.1%/annum vs -1.6%; lateral tibia: -1.9%/annum vs -1.6%; p≤0.02), progressive ROA and TKR (OR range 1.5 to 2.4; 95% CI range 1.1 to 3.4, p≤0.02). In those with no ROA, a baseline medial meniscal extrusion was associated with accelerated cartilage loss (medial tibia: -2.1%/annum vs. -1.2%, p&lt;0.001) and a baseline medial BML with incident ROA (OR 1.7, 95% CI 1.1 to 2.9, p=0.03). <h3>Conclusions</h3> Baseline meniscal extrusion and BMLs predict incident and progressive knee OA and represent important and independent structural targets for patient selection in disease-modifying OA drug (DMOAD) trials. <h3>Disclosure of Interest</h3> J. Martel-Pelletier Shareholder of: ArthroLab Inc., A. Teichtahl: None declared, F. Cicuttini: None declared, F. Abram Employee of: ArthroLab Inc., Y. Wang: None declared, J.-P. Pelletier Shareholder of: ArthroLab Inc.
Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.
Authors: Razelle Kurzrock, Paul Hamlin, Anas Younes, David Hong, Michael Gordon, Matthew A. Spear, Michael A. Palladino, G. Kenneth Lloyd, Angie M. Longenecker, Saskia T.C. Neuteboom, Gillian F. Cropp, Alison Hannah, Carol Aghajanian
Journal: Blood (2007)